Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
The Evaluation Gap in Medicine, AI and LLMs: Navigating Elusive Ground Truth & Uncertainty via a Probabilistic Paradigm
arXiv:2601.05500v1 Announce Type: new Abstract: Benchmarking the relative capabilities of AI systems, including Large Language Models (LLMs) and Vision Models, typically ignores the impact of uncertainty in the underlying ground truth answers from experts. This ambiguity is particularly consequential in medicine where uncertainty is pervasive. In this paper, we introduce a probabilistic paradigm to theoretically explain how high certainty in ground truth answers is almost always necessary for e
-
cs.AI, q-bio.NC updates on arXiv.org
-
Safety Not Found (404): Hidden Risks of LLM-Based Robotics Decision Making
arXiv:2601.05529v1 Announce Type: new Abstract: One mistake by an AI system in a safety-critical setting can cost lives. As Large Language Models (LLMs) become integral to robotics decision-making, the physical dimension of risk grows; a single wrong instruction can directly endanger human safety. This paper addresses the urgent need to systematically evaluate LLM performance in scenarios where even minor errors are catastrophic. Through a qualitative evaluation of a fire evacuation scenario, w
Safety Not Found (404): Hidden Risks of LLM-Based Robotics Decision Making
-
cs.AI, q-bio.NC updates on arXiv.org
-
A Survey of Agentic AI and Cybersecurity: Challenges, Opportunities and Use-case Prototypes
arXiv:2601.05293v1 Announce Type: cross Abstract: Agentic AI marks an important transition from single-step generative models to systems capable of reasoning, planning, acting, and adapting over long-lasting tasks. By integrating memory, tool use, and iterative decision cycles, these systems enable continuous, autonomous workflows in real-world environments. This survey examines the implications of agentic AI for cybersecurity. On the defensive side, agentic capabilities enable continuous monit
A Survey of Agentic AI and Cybersecurity: Challenges, Opportunities and Use-case Prototypes
-
cs.AI, q-bio.NC updates on arXiv.org
-
Streamlining evidence based clinical recommendations with large language models
arXiv:2505.10282v2 Announce Type: replace-cross Abstract: Clinical evidence underpins informed healthcare decisions, yet integrating it into real-time practice remains challenging due to intensive workloads, complex procedures, and time constraints. This study presents Quicker, an LLM-powered system that automates evidence synthesis and generates clinical recommendations following standard guideline development workflows. Quicker delivers an end-to-end pipeline from clinical questions to recomm
Streamlining evidence based clinical recommendations with large language models
-
cs.AI, q-bio.NC updates on arXiv.org
-
CliCARE: Grounding Large Language Models in Clinical Guidelines for Decision Support over Longitudinal Cancer Electronic Health Records
arXiv:2507.22533v2 Announce Type: replace-cross Abstract: Large Language Models (LLMs) hold significant promise for improving clinical decision support and reducing physician burnout by synthesizing complex, longitudinal cancer Electronic Health Records (EHRs). However, their implementation in this critical field faces three primary challenges: the inability to effectively process the extensive length and fragmented nature of patient records for accurate temporal analysis; a heightened risk of
CliCARE: Grounding Large Language Models in Clinical Guidelines for Decision Support over Longitudinal Cancer Electronic Health Records
-
cs.AI, q-bio.NC updates on arXiv.org
-
Benchmarking LLM-based Agents for Single-cell Omics Analysis
arXiv:2508.13201v2 Announce Type: replace-cross Abstract: The surge in multimodal single-cell omics data exposes limitations in traditional, manually defined analysis workflows. AI agents offer a paradigm shift, enabling adaptive planning, executable code generation, traceable decisions, and real-time knowledge fusion. However, the lack of a comprehensive benchmark critically hinders progress. We introduce a novel benchmarking evaluation system to rigorously assess agent capabilities in single-
Benchmarking LLM-based Agents for Single-cell Omics Analysis
-
FDA Press Releases RSS Feed
-
FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation
The U.S. Food and Drug Administration today announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing and control (CMC) requirements for cell and gene therapies (CGT).
FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation
-
TechCrunch
-
Google removes AI Overviews for certain medical queries
This follows an investigation by the Guardian that found Google AI Overviews offering misleading information in response to some health-related queries.
Google removes AI Overviews for certain medical queries
-
STAT

-
Opinion: The NIH has lost its scientific integrity. So we left
We are National Institutes of Health scientists and administrators with more than 50 years of collective civil service. Or, more accurately, we were NIH scientists and administrators.Read the rest…
Opinion: The NIH has lost its scientific integrity. So we left
We are National Institutes of Health scientists and administrators with more than 50 years of collective civil service.
Or, more accurately, we were NIH scientists and administrators.


© Adobe
-
MRD
-
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making
Cancers (Basel). 2025 Dec 27;18(1):94. doi: 10.3390/cancers18010094.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor long-term survival despite advances in surgical techniques, systemic therapies, and perioperative management. High rates of systemic recurrence following curative-intent resection suggest that many patients harbor minimal residual disease (MRD), microscopic tumor burden that persists postoperatively and remains undetectable by conventiona
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making
Cancers (Basel). 2025 Dec 27;18(1):94. doi: 10.3390/cancers18010094.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor long-term survival despite advances in surgical techniques, systemic therapies, and perioperative management. High rates of systemic recurrence following curative-intent resection suggest that many patients harbor minimal residual disease (MRD), microscopic tumor burden that persists postoperatively and remains undetectable by conventional diagnostic tools. Recent advances in liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) analysis, alongside detailed characterization of the PDAC mutational landscape, offer a promising non-invasive approach for MRD detection. Emerging evidence indicates that MRD status can serve as a sensitive prognostic biomarker, identify patients at high risk of relapse, and guide personalized perioperative therapy, including optimization of adjuvant treatment. This review summarizes current knowledge on the biology and detection of MRD in PDAC, its implications for perioperative risk stratification and treatment decision-making, and discusses future directions for integrating MRD assessment into clinical practice to enable more precise, individualized patient management.
PMID:41514607 | PMC:PMC12784771 | DOI:10.3390/cancers18010094
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Integrative Genomic and AI Approaches to Lung Cancer and Implications for Disease Prevention in Former Smokers
Int J Mol Sci. 2026 Jan 4;27(1):521. doi: 10.3390/ijms27010521.ABSTRACTTobacco smoking accounts for nearly 90% of lung cancer deaths worldwide, yet the mechanisms underlying persistent cancer risk in former smokers are not fully understood. Epidemiological evidence shows that more than 40% of lung cancers develop over 15 years after cessation, demonstrating that while some smoking-induced molecular alterations resolve rapidly, others remain as long-lasting scars that promote carcinogenesis. This
Integrative Genomic and AI Approaches to Lung Cancer and Implications for Disease Prevention in Former Smokers
Int J Mol Sci. 2026 Jan 4;27(1):521. doi: 10.3390/ijms27010521.
ABSTRACT
Tobacco smoking accounts for nearly 90% of lung cancer deaths worldwide, yet the mechanisms underlying persistent cancer risk in former smokers are not fully understood. Epidemiological evidence shows that more than 40% of lung cancers develop over 15 years after cessation, demonstrating that while some smoking-induced molecular alterations resolve rapidly, others remain as long-lasting scars that promote carcinogenesis. This review synthesizes longitudinal and cross-sectional genomic, epigenomic, and transcriptomic studies of airway and lung tissues to distinguish persistent from nonpersistent smoking-induced molecular alterations. Persistent alterations include somatic mutations in TP53 and KRAS, DNA methylation at tumor suppressor loci, dysregulated noncoding RNAs, chromosomal instability, and epigenetic age acceleration. Nonpersistent changes, such as acute inflammatory responses and detoxification pathways, generally normalize within months to several years following cessation. Multi-omics profiling reveals coordinated patterns of dysregulation consistent with field cancerization in former smokers. In addition, the integration of multi-omics data with artificial intelligence may enable composite molecular signatures for stratifying high-risk former smokers, link molecular persistence to clinical outcomes, and inform chemoprevention strategies. Collectively, these observations clarify which molecular alterations sustain long-term cancer risk despite smoking cessation and highlight opportunities for precision prevention and earlier detection in high-risk populations.
PMID:41516393 | PMC:PMC12786486 | DOI:10.3390/ijms27010521